Filing Flows › Coherus Oncology (CHRS) › Guidance & outlook

Coherus Oncology (CHRS) guidance and outlook

Coherus Oncology (CHRS) lowered its guidance on Nov 9, 2026: Revenue (segment) $25.0M–$30.0M for FY2026. Coherus Oncology's 10-Q filed Nov 9, 2026 makes 15 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 9, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 9, 2026

• We are a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting esophageal, liver, and prostate cancers.
• We have global rights to both our clinical-stage candidates and intend to explore transactions, including ex-U.S. licensing, as clinical data emerges for these candidates.
• Further evaluation of LOQTORZI is expected through multiple current and planned clinical studies by us and our partners.
• Under the terms of the clinical supply agreement, Janssen will provide pasritamig to us, and we will be the sponsor of the Phase 1b clinical trial.
• We expect net revenue from continuing operations in 2026 to be higher than in 2025 because of continued growth of LOQTORZI.
• We expect cost of goods sold from continuing operations for 2026 to be higher than 2025 because of continued growth of LOQTORZI.
• We expect our fixed research and development expenses in 2026 to be lower than in 2025 primarily due to lower expenditures on manufacturing-related development activities and reduced headcount.
• We expect our selling, general and administrative expense from continuing operations for the full year 2026 to be lower than the full year 2025 primarily as a result of decreased operating costs and headcount.
• We expect interest expense from continuing operations to be slightly higher in 2026 as compared to 2025.
• In addition, we expect we will require additional financing through equity and/or debt financing, collaborations, licensing arrangements or other sources to fully develop, obtain regulatory approval for and commercialize our existing product candidates.
• The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern.
• Management’s plans to address these conditions include deprioritizing certain tagmokitug clinical indications, the implementation of a cost reduction plan, including decreasing headcount, pursuing receipt of an Earnout Payment from the Intas Parties, accelerating LOQTORZI sales, and raising additional equity capital as needed.

Coherus Oncology's latest quarter

Questions

Did Coherus Oncology raise or lower its guidance?

Coherus Oncology (CHRS) lowered its guidance on Nov 9, 2026: Revenue (segment) $25.0M–$30.0M for FY2026.

What does Coherus Oncology expect?

We are a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting esophageal, liver, and prostate cancers. We have global rights to both our clinical-stage candidates and intend to explore transactions, including ex-U.S. licensing, as clinical data emerges for these candidates. Further evaluation of LOQTORZI is expected through multiple current and planned clinical studies by us and our partners.

Open the interactive view →

Updated Nov 10, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.